20250808-深圳来觅数据信息科技-生物技术2025年二季度投融市场报告_22页_2mb

Summary of Biotechnology Q2 2025 Investment and Financing Market Report

Industry Overview

In the first half of 2025, the biotechnology sector experienced significant advancements driven by policy support and technological innovation. Key subfields include innovative biologics, biological breeding, and life sciences. AI integration boosted R&D efficiency and innovation drug exports, with China recording high-value BD transactions abroad. Relevant policies focus on supporting R&D using healthcare data, streamlining clinical trials, and funding synthetic biology, demonstrating a government commitment to the biotech ecosystem.

Q2 Investment Dynamics

During Q2 2025, the biotechnology sector saw 136 financing deals totaling 40.61 billion RMB, with the highest activity in biologics, agriculture, and life sciences. Financing concentrated in eastern Chinese provinces, with early-stage investments (Angel to A rounds) dominating both in number and funding (66.18% of cases and 46.54% of amount). Active investors include firms like Shenzhen Capital and Yuan Sheng Venture Capital, focusing on areas such as synthetic biology and RNA drugs.

Key Trends and Policies

Emerging trends highlight AI's role in life sciences, like the OpenCRISPR-1 gene editor, offering advantages in precision and safety. Biologic veterinary drugs are growing due to antibiotic reduction policies, driven by consumer demand for safer animal products. Q2 showcased a surge in investments targeting sustainable alternatives, such as phage therapies, reflecting market shifts post-"no antibiotic" regulations.

Representative Enterprise: GeRuan Bio

GeRuan Bio, a leading biotech company in veterinary phage therapy, has raised 1.2 billion RMB to develop solutions for animal diseases. The company's R&D efforts align with national policies reducing antibiotic use, positioning it for rapid growth in the biologic veterinary market, potentially accelerating adoption in large-scale farming.

Q2 Key Events Highlights

• Significant investments in companies like Jinyin Pharma and Hao Bo Medicine, focusing on RNA drugs and synthetic biology.
• Policy releases from agencies like the Ministry of Agriculture and National Medical Security Administration, enhancing R&D support and clinical trial efficiencies.